parp inhibitors as first-line maintenance therapy in ovarian cancer
Published 2 years ago • 315 plays • Length 59:02Download video MP4
Download video MP3
Similar videos
-
35:35
maximizing the potential of parp inhibitors as first-line maintenance therapy in ovarian cancer
-
59:14
parp inhibitors in ovarian cancer: clinical updates from sgo 2023
-
1:26
parp inhibitors for maintenance therapy in ovarian cancer
-
19:09
ecco 2017 - a new parp inhibitor to clinical practice - part 4
-
58:46
learn all about parp inhibitors with dr jon krell, consultant medical oncologist
-
9:47
can parp inhibitors offer benefit for all patients with platinum-sensitive ovarian cancer?
-
7:10
jonathan a ledermann – maintenance treatment for recurrent ovarian carcinoma
-
0:45
evaluating future use of parp inhibitors in neoadjuvant therapy for ovarian cancer
-
3:06
recurrent ovarian cancer: choosing a parp inhibitor
-
1:03:39
precision medicine in ovarian cancer with parp inhibitor therapy and companion diagnostics
-
1:04
olaparib maintenance therapy in ovarian cancer
-
3:58
the potential of parp inhibitors in ovarian cancer: paola-1, prima & velia
-
1:25
dr. konecny on the indications for parp inhibitors in recurrent ovarian cancer
-
1:27
parp inhibition improves outcomes in patients with brca-mutated ovarian cancer
-
3:44
the future role of parp inhibition in ovarian cancer
-
7:56
maintenance therapy in ovarian cancer
-
1:08
should 1l maintenance with parp inhibitors be given to all patients with ovarian cancer?
-
57:11
personalizing advanced ovarian cancer treatment with parp inhibitors and novel approaches
-
1:22
dr. penson on the eligibility criteria for parp inhibitors in advanced ovarian cancer